MNKDMannkind Corporation

CSNasdaq (XNAS)·USD

Identity

Security key: 18666
Ticker: MNKD
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2004-07-28
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: MNKD

Detail

Enriched 2026-08-14 20:47

Market cap: $1,237,931,452.45
Shares outstanding (class): 321,540,637
Shares outstanding (weighted): 321,540,637
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 592
Location: DANBURY, CT
Homepage: https://www.mannkindcorp.com
Description: MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Market cap and share counts drift.

Funds holding this security

82 funds · 82 positions · $105.04M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$26.79M	0.36%	10,933,657 NS	FIGI
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$22.41M	0.00%	9,147,582 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$18.28M	0.03%	7,462,646 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$8.40M	0.01%	3,429,432 NS	FIGI
iShares Russell 2000 Growth ETF iShares Trust	IWO	$6.12M	0.05%	2,497,673 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$5.39M	0.07%	2,199,381 NS	FIGI
VictoryShares Small Cap Free Cash Flow ETF Victory Portfolios II	SFLO	$2.94M	0.60%	1,198,282 NS	FIGI
Master Small Cap Index Series Quantitative Master Series LLC	—	$1.21M	0.03%	495,459 NS	FIGI
iShares Core S&P Total U.S. Stock Market ETF iShares Trust	ITOT	$1.11M	0.00%	451,085 NS	FIGI
State Street(R) SPDR(R) S&P Kensho New Economie… SPDR SERIES TRUST	KOMP	$878.9K	0.04%	358,748 NS	FIGI
Principal U.S. Small-Cap ETF Principal Exchange-Traded Funds	PSC	$807.7K	0.05%	329,665 NS	FIGI
EQ/2000 Managed Volatility Portfolio EQ Advisors Trust	—	$801.7K	0.02%	327,207 NS	FIGI
Fidelity Enhanced Small Cap ETF Fidelity Covington Trust	FESM	$704.1K	0.02%	287,379 NS	FIGI
VANGUARD STRATEGIC SMALL-CAP EQUITY FUND VANGUARD HORIZON FUNDS	—	$581.9K	0.02%	237,523 NS	FIGI
Fidelity Small Cap Growth Index Fund Fidelity Salem Street Trust	—	$569.9K	0.05%	232,605 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERMNKD
FIGI_COMPOSITEBBG000PPL3G9
FIGI_SHARE_CLASSBBG001SLLLY3
CIK0000899460
ISINUS56400P7069
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Pharmaceuticals
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Mannkind is a biopharmaceutical company focused on developing and commercializing inhaled therapeutic products, classified under pharmaceutical preparations.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.